Ferraro D, Falaschi F, Nazzaro L, Vennarecci G. Impact of neoadjuvant multimodal therapy in the setting of locally advanced hepatocellular carcinoma. World J Gastroenterol 2024; 30(28): 3452-3455 [PMID: 39091715 DOI: 10.3748/wjg.v30.i28.3452]
Corresponding Author of This Article
Daniele Ferraro, MD, Consultant in HPB Surgery and Liver Transplantation, Hepato-biliary and Liver Transplant Centre, Department of General Surgery and Woman’s Health, AORN Antonio Cardarelli, Naples 80131, Italy. daniele.ferraro@aocardarelli.it
Research Domain of This Article
Surgery
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jul 28, 2024; 30(28): 3452-3455 Published online Jul 28, 2024. doi: 10.3748/wjg.v30.i28.3452
Impact of neoadjuvant multimodal therapy in the setting of locally advanced hepatocellular carcinoma
Daniele Ferraro, Federica Falaschi, Luca Nazzaro, Giovanni Vennarecci
Daniele Ferraro, Federica Falaschi, Luca Nazzaro, Giovanni Vennarecci, Hepato-biliary and Liver Transplant Centre, Department of General Surgery and Woman’s Health, AORN Antonio Cardarelli, Naples 80131, Italy
Author contributions: Ferraro D, Falaschi F, Nazzaro L, and Vennarecci G equally contributed to the study design, research, data analysis, writing, and revision of the letter; and all authors read and approved the final version of the manuscript.
Conflict-of-interest statement: We declare having no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Daniele Ferraro, MD, Consultant in HPB Surgery and Liver Transplantation, Hepato-biliary and Liver Transplant Centre, Department of General Surgery and Woman’s Health, AORN Antonio Cardarelli, Naples 80131, Italy. daniele.ferraro@aocardarelli.it
Received: April 29, 2024 Revised: May 28, 2024 Accepted: July 2, 2024 Published online: July 28, 2024 Processing time: 86 Days and 5.7 Hours
Abstract
Immunotherapy and the implementation of more aggressive treatment schemes for locally advanced hepatocellular carcinomas have expanded the boundaries of curative options. Because of these advancements, patients who were once considered beyond the aim of a cure are now eligible for liver transplantation and resection.
Core Tip: The field of treatment for hepatocellular carcinoma is constantly evolving due to the advances in highly effective chemotherapeutic regimens. The possible use of drugs in the neoadjuvant setting as a powerful downstaging tool opens up the possibility of liver transplantation or liver resection for patients once deemed incurable. The use of these drugs in the adjuvant therapy setting could reinforce the results of surgery in the treatment of hepatocellular carcinoma.
